Literature DB >> 25682769

Interferon-γ release assay vs. tuberculin skin test for tuberculosis screening in exposed healthcare workers: a longitudinal multicenter comparative study.

Jean-Christophe Lucet1, Dominique Abiteboul2, Candice Estellat3, Carine Roy3, Sylvie Chollet-Martin4, Florence Tubach3, Guislaine Carcelain5.   

Abstract

OBJECTIVE: Healthcare workers (HCWs), especially those caring for patients with tuberculosis (TB), are at high risk of acquiring that disease. The poor specificity of tuberculin skin testing (TST) prompted us to evaluate the effectiveness of the interferon-γ release assay (IGRA) in comparison with TST in a large prospective, multicenter, 1-year study of HCWs with occupational exposure to TB.
METHODS: HCWs from high-risk units at 14 university hospitals were invited to participate and underwent both TST and IGRA (first Quantiferon TB Gold-IT®, QFT-G, then T-SPOT.TB® if QFT-G was indeterminate) at baseline and after 1 year. We collected demographic characteristics, country of birth, history of TB, immunosuppression, past exposure to TB, history of BCG vaccination, results of most recent TST, job category, and duration of current function.
RESULTS: Among 807 HCWs enrolled, current or past TST at baseline was positive (≥15 mm) in 282 (34.9%); the IGRA was positive in 113 (14.0%) and indeterminate in 3 (0.4%). After 1 year, 594 HCWs had both an IGRA and TST (or prior TST≥15 mm) at baseline and an IGRA and TST (if indicated). The conversion rate was 2.5% (9 of 367) with TST and 7.6% (45 of 594) with IGRA, with poor agreement between the 2 tests. Using only QFT-G, conversion (9.9%) and reversion (17.8%) rates were higher for baseline QFT-G positive quantitative values <1 IU/mL.
CONCLUSION: TST and the IGRA yielded discordant results. The value of IGRA in addition to TST remains undetermined; the two should be jointly interpreted in decision-making (clinical trial registration NCT00797836).

Entities:  

Mesh:

Year:  2015        PMID: 25682769     DOI: 10.1017/ice.2015.19

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  Paradox of serial interferon-gamma release assays: variability width more important than specificity size.

Authors:  J E Stout; R Belknap; Y-J Wu; C S Ho
Journal:  Int J Tuberc Lung Dis       Date:  2018-05-01       Impact factor: 3.427

2.  Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis.

Authors:  Tan N Doan; Damon P Eisen; Morgan T Rose; Andrew Slack; Grace Stearnes; Emma S McBryde
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

3.  T-SPOT®.TB Test for Latent Tuberculosis Infection Diagnosis and Treatment Guidance in Thai Health-Care Professionals.

Authors:  Thana Khawcharoenporn; Waralee Aksornchindarat; Napat Yodpinij; Sopa Srisungngam; Janisara Rudeeaneksin; Supranee Bunchoo; Wiphat Klayut; Somchai Sangkitporn; Benjawan Phetsuksiri
Journal:  Indian J Occup Environ Med       Date:  2020-03-18

4.  QuantiFERON-TB Gold Plus Assay in Patients With Latent vs. Active Tuberculosis in a Low Incidence Setting: Level of IFN-γ, CD4/CD8 Responses, and Release of IL-2, IP-10, and MIG.

Authors:  Séverine Carrère-Kremer; Pratt Kolia-Diafouka; Amandine Pisoni; Karine Bolloré; Marianne Peries; Sylvain Godreuil; Arnaud Bourdin; Philippe Van de Perre; Edouard Tuaillon
Journal:  Front Microbiol       Date:  2022-04-08       Impact factor: 5.640

5.  Risk of Occupational Latent Tuberculosis Infection among Health Personnel Measured by Interferon-Gamma Release Assays in Low Incidence Countries-A Systematic Review and Meta-Analysis.

Authors:  Claudia Peters; Agnessa Kozak; Albert Nienhaus; Anja Schablon
Journal:  Int J Environ Res Public Health       Date:  2020-01-16       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.